Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
Date:5/8/2013

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2013. The conference call will include an update on development of bremelanotide for female sexual dysfunction, including plans for Phase 3 clinical trials and results of the end-of-Phase 2 meeting with the U.S. Food and Drug Administration.Schedule for the Financial Results Press Release, Conference Call / Webcast 

  • 3Q Fiscal Year 2013 Financial Results Press Release
  • 5/14/2013 at 7:30 a.m. ET

  • 3Q Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013 at 11:00 a.m. ET

    1-888-427-9419

    1-719-457-2648

    8591699

  • 3Q Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013-5/21/2013

    1-888-203-1112

    1-719-457-0820

    8591699

  • Webcast Live and Replay Access
  • http://www.palatin.com The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.comAbout Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com or follow us on Twitter at http://twitter.com/PalatinTech.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    2. Palatin Technologies To Present At The 25th Annual ROTH Conference
    3. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    4. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    5. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    7. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    9. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    10. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    11. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
    (Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
    (Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
    (Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
    Breaking Biology Technology:
    (Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
    (Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
    (Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
    Breaking Biology News(10 mins):